Andrew Serafin

Mr. Serafin is the Chief Strategy Officer at Harmony Biosciences and is responsible for leading the company’s corporate strategy, business and corporate development initiatives, and alliance management efforts, including the expansion of the company’s pipeline through the acquisition and licensing of novel rare disease therapies for patients with high, unmet needs.

Mr. Serafin has 20 years of experience in mergers and acquisitions and corporate legal counseling in the pharmaceutical, broader healthcare, and technology sectors. Mr. Serafin previously served as Vice President of Business Development at Marathon Pharmaceuticals, LLC, Vice President of M&A and General Counsel at AltaThera Pharmaceuticals, and Vice President of U.S. Legal Affairs and Associate General Counsel at Lundbeck Inc., where he oversaw and executed on transactions with valuations of up to $1 billion.

Mr. Serafin began his career in private legal practice, where he specialized in corporate transactions, provided strategic legal and business consulting advice to clients, and consummated both public and private deals, including acquisitions, divestitures, and collaborations.

He holds a Bachelor of Science degree from the University of Illinois, a Juris Doctor from the Loyola University Chicago School of Law, and a Masters of Business Administration from the Northwestern University Kellogg School of Management.